Population health: Innovation and outcomes for every community
At Bristol Myers Squibb, we believe that every person should have an equitable opportunity to benefit from our medicines and innovation, no matter who they are, where they live or what they have. Health equity is the lens through which we advance population health — guiding how we discover, develop and deliver medicines so that our science reflects and reaches the real-world populations affected by disease.
Advancing health equity is essential to delivering on our mission. We recognize that even the most advanced treatment has limited impact if patients cannot access it, understand it or trust the care they receive. Taking a population level approach, we work to identify and address systemic barriers that limit access to care, participation in research and patient outcomes. We work side by side with communities — listening, learning and building together to help ensure our science translates into real‑world impact where people live, work and receive care.
For BMS, health equity is a scientific, business and societal imperative that strengthens trust and delivers sustainable impact for patients worldwide. When our science reflects real world populations and care pathways support understanding, access and trust, we enable better innovations and more equitable patient outcomes.
Our focus:
Inclusive research
Inclusive research is how Bristol Myers Squibb designs and delivers more accessible and representative clinical trials — and ultimately, better medicines. By embedding inclusive research as a scientific best practice across the clinical development lifecycle, we work to ensure that clinical trials reflect the populations affected by disease.
We focus on reducing barriers that can limit participation for patients in medically underserved and underrepresented populations by building trial-ready communities and evolving where and how clinical trials are conducted. This approach strengthens scientific rigor, supports regulatory confidence and builds trust by ensuring research is designed with inclusion in mind from the outset.
Equitable access to care
We are committed to addressing challenges related to access, quality and continuity of care in the United States and globally.
Our work focuses on strengthening support throughout the patient journey in our therapeutic areas of focus: neuroscience, cardiovascular and oncology — including multiple myeloma and lung cancer — where persistent gaps in access and outcomes exist. Through a population health approach, we also work to expand sustainable access to innovative medicines in low- and middle-income countries, where health system constraints can limit the ability to benefit from medical innovation.
How we deliver this work
